Past studies have shown that chemotherapeutics do not cross the blood-brain barrier; however, recent studies have shown that platinum combined with cytotoxic drugs can benefit patients.7 With the advances in research, targeted therapy has increasingly become one of the important means to treat NSCLC with brain metastasis.8 Epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) is currently widely used in the treatment of NSCLC. Here, EGFR is linked to non-small cell lung carcinoma.